1. Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs
- Author
-
Alfonso Mendoza, Cindy Richards, Modesto J. Remuiñán, Joaquín Rullas, Iñigo Angulo-Barturen, Delia Blanco, Ermias Woldu, Julia Castro, Esther Pérez-Herrán, Ruben Gonzalez Del Rio, Monica Cacho, María Jesús Vázquez-Muñiz, David Barros, Jose Luis Lavandera, Lluis Ballell, and María Cleofé Zapatero-González
- Subjects
Models, Molecular ,Tuberculosis ,medicine.drug_class ,Antitubercular Agents ,Microbial Sensitivity Tests ,Topoisomerase-I Inhibitor ,Pharmacology ,DNA gyrase ,Mycobacterium tuberculosis ,Mice ,In vivo ,Drug Discovery ,medicine ,Animals ,Pharmacology (medical) ,Enzyme Inhibitors ,Mechanisms of Action: Physiological Effects ,Mycobacterium bovis ,biology ,Drug discovery ,biology.organism_classification ,medicine.disease ,Mice, Inbred C57BL ,Infectious Diseases ,Female ,Topoisomerase I Inhibitors ,Topoisomerase inhibitor ,Fluoroquinolones - Abstract
One way to speed up the TB drug discovery process is to search for antitubercular activity among compound series that already possess some of the key properties needed in anti-infective drug discovery, such as whole-cell activity and oral absorption. Here, we present MGIs, a new series of Mycobacterium tuberculosis gyrase inhibitors, which stem from the long-term efforts GSK has dedicated to the discovery and development of novel bacterial topoisomerase inhibitors (NBTIs). The compounds identified were found to be devoid of fluoroquinolone (FQ) cross-resistance and seem to operate through a mechanism similar to that of the previously described NBTI GSK antibacterial drug candidate. The remarkable in vitro and in vivo antitubercular profiles showed by the hits has prompted us to further advance the MGI project to full lead optimization.
- Published
- 2015
- Full Text
- View/download PDF